drugset / Trial / NCT06376721
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.
Timeline
- Start
- 2024-04-14
- Primary completion
- 2026-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Linperlisib | Small molecule | 80 mg | Oral |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 unknown | Intramuscular |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |